With two-thirds of the year gone, there are six vaccine candidates in Phase-3 or Phase 2/3 trials, according to WHO. Three of these are Chinese – from Sinovac, Sinopharm and the Wuhan Institute of Biological Products, and Sinopharm and the Beijing Institute of Biological Products
